Raphael Pharmaceutical (RAPH) Interest Expenses (2020 - 2025)

Raphael Pharmaceutical (RAPH) has 6 years of Interest Expenses data on file, last reported at $2.0 million in Q4 2025.

• For the quarter ending Q4 2025, Interest Expenses rose 29.19% year-over-year to $2.0 million; the trailing twelve-month figure through Dec 2025 stood at $2.0 million (up 29.19% YoY), and the FY2025 full-year result was $2.0 million, up 29.19% from the prior year.
• Interest Expenses rose to $2.0 million in Q4 2025, from $1.5 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $2.0 million in Q4 2025 to a low of $727000.0 in Q4 2022.
• A 5-year average of $1.4 million and a median of $1.3 million in 2023 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses jumped 686.71% in 2021 and tumbled 41.51% in 2022, its largest moves.
• Tracing RAPH's Interest Expenses over 5 years: stood at $1.2 million in 2021, then plunged by 41.51% to $727000.0 in 2022, then jumped by 74.69% to $1.3 million in 2023, then increased by 21.1% to $1.5 million in 2024, then advanced by 29.19% to $2.0 million in 2025.
• Business Quant data shows RAPH's Interest Expenses at $2.0 million in Q4 2025, $1.5 million in Q4 2024, and $1.3 million in Q4 2023.